Is BioRestorative Therapies, Inc. (BRTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 233.3% / 30% | 4.1% / 30% | 153.64% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 233.3% / 33% | 4.1% / 33% | 153.64% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 87.4% / 33% | 1.5% / 33% | 153.64% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 233.3% / 33% | 4.1% / 33% | 153.64% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 87.4% / 33% | 1.5% / 50% | 153.64% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 93.3% | |
| Operating Margin | -31432.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -207.7% | |
| Return on Assets (ROA) | -89.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $0 |
| Current Ratio | 1.4 |
| Total Assets | $12M |
Price & Trading
| Last Close | $0.30 |
| 50-Day MA | $0.56 |
| 200-Day MA | $1.22 |
| Avg Volume | 9.2M |
| Beta | 0.4 |
|
52-Week Range
$0.19
| |
About BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioRestorative Therapies, Inc. (BRTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioRestorative Therapies, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioRestorative Therapies, Inc.'s debt ratio?
BioRestorative Therapies, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are BioRestorative Therapies, Inc.'s key financial metrics?
BioRestorative Therapies, Inc. has a market capitalization of $6M, and revenue of $401,000. Return on equity stands at -207.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.